MarketPeel
Insider Trading Intelligence
MW

Mats Wahlstrom

CHRS
DIRECTOR · COHERUS ONCOLOGY, INC. · CIK 0001459154
FILING MIX · LIFETIME79%/21%
BUYS
27
SELLS
7
TOTAL VALUE
$6.48M
COMPANIES
2
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
177,555
AVG SELL PX
$14.06
TRADE KIND
SHOWING 34 / 34
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 4 pending
Forward-return performance of every backtestable P/S trade by Mats Wahlstrom, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+71.43%-2.39%-0.66%-1.73%-0.52%
14d7+57.14%-6.78%-2.99%-3.79%-1.68%
30d7+42.86%-8.71%-3.34%-5.37%-7.93%
60d7+71.43%+5.73%+1.72%+4.00%+7.28%
90d7+71.43%+20.68%+4.92%+15.76%+23.43%
180d7+71.43%+17.43%+9.70%+7.73%+20.72%
1y7+85.71%+13.94%+22.70%-8.76%+0.55%
2y7(4 pending)+100.00%-48.35%+40.33%-88.69%-90.75%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CHRS · 30,000 shares · as of Jun 5, 2026
051,056102,111153,167204,222202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 27 buys / 7 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
60,00060,000Jun 5, 2026Jun 9, 2026View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
30,00030,000Jun 5, 2026Jun 9, 2026View →
TLSI
TRISALUS LIFE SCIENCES, INC.
PURCHASE
60,000$2.53$151.8K147,555May 15, 2026May 18, 2026View →
TLSI
TRISALUS LIFE SCIENCES, INC.
PURCHASEGRANT
Stock grant
75,204276,149May 14, 2026May 15, 2026View →
TLSI
TRISALUS LIFE SCIENCES, INC.
PURCHASEGRANT
Stock grant
37,60253,329May 14, 2026May 15, 2026View →
TLSI
TRISALUS LIFE SCIENCES, INC.
PURCHASEGRANT
Stock grant
34,22687,555May 14, 2026May 15, 2026View →
TLSI
TRISALUS LIFE SCIENCES, INC.
PURCHASEGRANT
Stock grant
15,000200,945Jun 12, 2025Jun 27, 2025View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
112,000112,000Jun 12, 2025Jun 13, 2025View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
99,988$0.74$73.9K0May 23, 2025May 28, 2025View →
TLSI
TRISALUS LIFE SCIENCES, INC.
PURCHASE
44,75094,750Feb 10, 2025Feb 11, 2025View →
TLSI
TRISALUS LIFE SCIENCES, INC.
PURCHASEGRANT
Stock grant
25,188$3.97$100.0K40,915Dec 17, 2024Dec 19, 2024View →
TLSI
TRISALUS LIFE SCIENCES, INC.
PURCHASE
5,000$4.55$22.8K15,727Nov 22, 2024Nov 25, 2024View →
TLSI
TRISALUS LIFE SCIENCES, INC.
PURCHASE
8,687$4.44$38.6K10,727Nov 21, 2024Nov 22, 2024View →
TLSI
TRISALUS LIFE SCIENCES, INC.
PURCHASE
2,040$4.16$8.5K2,040Nov 20, 2024Nov 22, 2024View →
TLSI
TRISALUS LIFE SCIENCES, INC.
PURCHASEGRANT
Stock grant
15,00015,000Aug 13, 2024Aug 21, 2024View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
112,000112,000Jun 3, 2024Jun 5, 2024View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Gift
99,98899,988Feb 9, 2024Feb 15, 2024View →
CHRS
COHERUS ONCOLOGY, INC.
SALEGRANT
Gift
99,9880Feb 9, 2024Feb 15, 2024View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
44,991$1.67$75.0K99,988Feb 1, 2024Feb 5, 2024View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
14,997$1.67$25.0K54,997Feb 1, 2024Feb 5, 2024View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
44,9910Feb 1, 2024Feb 5, 2024View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
14,9970Feb 1, 2024Feb 5, 2024View →
TLSI
TRISALUS LIFE SCIENCES, INC.
PURCHASEGRANT
Stock grant
35,00035,000Aug 10, 2023Aug 14, 2023View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
38,25038,250Jun 7, 2023Jun 9, 2023View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
29,994$2.08$62.5K40,000Feb 28, 2022Mar 1, 2022View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
29,9940Feb 28, 2022Mar 1, 2022View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
10,006$11.64$116.4K10,006Feb 25, 2022Mar 1, 2022View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
27,00027,000Jan 7, 2022Feb 11, 2022View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
27,00027,000Jan 7, 2022Jan 7, 2022View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
20,00020,000Jan 11, 2021Jan 13, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
200,000$17.15$3.43M0Jun 17, 2020Jun 19, 2020View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
4,222$20.89$88.2K200,000Mar 3, 2020Mar 5, 2020View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
113,844$20.09$2.29M204,222Mar 3, 2020Mar 5, 2020View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
20,00020,000Jan 10, 2020Jan 14, 2020View →
Other insiders · CHRS
Loading peer insiders…
About this filer
CIK 0001459154
ROLE
Director
PRIMARY
CHRS
COMPANIES
2
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001459154DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback